6
Views
7
CrossRef citations to date
0
Altmetric
Research Article

LANGERHANS' CELL HISTIOCYTOSIS - STILL AN UNSOLVED PROBLEM

Pages 489-493 | Published online: 09 Jul 2009

References

  • Willman CL, Bisque L, Griffith BB, et al. Langerhans cell histiocytosis (histiocytosis X): a clonal proliferative disease. New Eng1J Med. 1994;331:154–160.
  • Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis: evolution and current approaches. Br J Cancer Suppl. 1994;23:S41–S46.
  • McLelland" Broadbent V, Yeomans E, Malone M, Pritchard" Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child. 1990;65:301–303.
  • Berry DH, GresikM, Maybee D, Marcus R. Histiocytosis X in bone only. Med Pediatr Oncol. 1990;18:292–294.
  • Fiorillo A, Sadile F, De-Chiara C, et al. Bone lesions in Langerhans cell histiocytosis. Clin Pediatr Phila. 1993;32:118–120.
  • Raney RB, D'Angio GJ. Langerhans' cell histiocytosis (histiocytosis X): experience at the Children's Hospital of Philadelphia, 1970-1984. Med Pediatr Oncol. 1989;17:20–28.
  • Ladisch S. Histiocytosis. In: Willoughby MNL, Siegel SE (eds). Butterworth's International Medical Re-views, vol 1: Pediatrics. London: Butterworths; 1983:95–109.
  • Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet. 1987;1:208–209.
  • Favara BE, Feller AC. Contemporary classification of histiocytic disorders. Med Pediatr Oncol 1997;29: 157–166.
  • Writing Group of the Histiocyte Society. Histiocytosis syndromes in children, II: approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Med Pediatr Oncol. 1989;17:492–495.
  • Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Henzatol Oncol Clin North Am. 1998;12:327–338.
  • Braier J, Chantada G, Rosso D, et al. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr Hematol Oncol 1999;16:377–385.
  • Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr OncoL 1994;23: 72–80.
  • Lahey E. Histiocytosis X: an analysis of prognostic factors. J PediatE 1975:184–189.
  • Lahey ME. Prognosis in reticuloendotheliosis in children. J Pediatr: 1962;60:664–671.
  • Komp DM, Herson J, Starling KA, Vietti TJ, Hvizdala E. A staging system for histiocytosis X: a Southwest Oncology Group Study. Cancer. 1981;47:798–800.
  • Lavin PT, Osband ME. Evaluating the role of therapy in histiocytosis-X. Hematol Oncol Clin North Am 1987;1:35–47.
  • Grois N, Minkov M, Heitger A, et al. Response to therapy in multisystem Langerhans cell histiocytosis (LCH): results from the DAL HX-83 and DAL HX-90 studies. Med Pediatr Oncol. 1996;27:573.
  • Komp DM, Mahdi AE, Starling KA, et al. Quality of survival in histiocytosis X: a Southwest Oncology Group Study. Med Pediatr Oncol 1980;8:35–40.
  • Sims DG. Histiocytosis X: follow-up of 43 cases. Arch Dis Child. 1977;52:433–440.
  • Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol. 1981;3:165–167.
  • The French Langerhans Cell Histiocytosis Study Group. A multicentre retrospective survey of Langer-ham cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child. 1996;75:17–24.
  • Osband ME, Lipton JM, Lavin P, et al. Histiocytosis X: demonstration of abnormal immunity, T-cell histamine H2-receptor deficiency and successful treatment with thymic extract. New Engif Med. 1981;304:146–153.
  • Ceci A, Terlizzi MD, Toma MG, et al. Heterogeneity of immunological patterns in LCH and response to crude calf thymic extract in 11 patients. Med Pediatr Oncol. 1988;16:111–115.
  • Jakobson A, Kreuger A, Hagberg H, Sundstrom C. Successful treatment of Langerhans' cell histiocy-tosis with alpha-interferon. Med Pediatr Oncol 1989;17:244–256.
  • Bellmunt J, Albanel1J, Salud A, et al. Interferon and disseminated Langerhans cell histiocytosis. Med Pediatr Oncol. 1992;20:336–337.
  • Mahmoud HH, Wang WC, Murphy SB. Cyclosporine therapy for advanced Langerhans cell histiocy-tosis. Blood. 1991;77:721–725.
  • Minkov M, Grois N, Broadbent V, et al. Cyclosporine A (GSA) therapy for multisystem Langerhans cell histiocytosis (MS-LCH). Med Pediatr Oncol 1998;31:45.
  • Kelly KM, Pritchard J. Monoclonal antibody therapy in Langerhans cell histiocytosis—feasible and reasonable? Br J Cancer Suppl 1994;23:S54—S55.
  • McLean TW, Pritchard J. Langerhans cell histiocytosis and hypercalcemia: clinical response to in-domethacin. J Pediatr Hematol Oncol 1996;18:318–320.
  • McCowage GB, Frush DP, Kurtzberg J. Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin. J Pediatr Hematol Oncol. 1996;18: 154–158.
  • Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994;121: 430–432.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.